AZD5305: Data from P1/2a PETRA trial (NCT04644068) for advanced solid malignancies post 2023 (AstraZeneca) - Nov 10, 2022 - Q3 2022 Results: Data from P1/2 PETRANHA trial (NCT05367440) for metastatic prostate cancer post 2023
P1/2 data • Breast Cancer • HER2 Negative Breast Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Triple Negative Breast Cancer
|